Changes to National Product List

Changes to products funded and supplied under the national blood arrangements

Interested parties, including patient groups or suppliers, can propose changes to the products or services that are publicly funded under the national blood arrangements.

Anyone wishing to make changes will be asked to provide evidence to support their proposal, including evidence-based evaluation of the product/service they nominate, as set out under Schedule 4 of the National Blood Agreement.

In order to make the application process consistent, a comprehensive Multi-Criteria Analysis Framework has been developed to assess proposals. Where appropriate, the Commonwealth’s Medical Services Advisory Committee (MSAC) health technology assessment process is also used to inform the cost effectiveness of proposals.  In September 2011, the Jurisdictional Blood Committee (JBC) established a working group to review and update the Schedule 4 and health technology assessment processes.

For detailed information on the Schedule 4 / Multi-Criteria Analysis Framework, please contact the NBA at or on  02 6151 5003.

Schedule 4 assessment - Alpha1-proteinase Inhibitor (A1-PI)  

In July and September 2017, the National Blood Authority received National Blood Supply Change Proposals for purified human alpha1-proteinase inhibitor (A1-PI) for the treatment of A1-PI deficiency, from Grifols (for the product Prolastin-C) and from CSL Behring (for the product Zemaira).

On 1 December 2017, JBC referred the two proposals to MSAC for assessment.  The assessment process included the opportunity for input through expert and public consultations.

MSAC considered the proposals on 22-23 November 2018.  After considering the strength of available evidence put forward in relation to comparative safety, clinical effectiveness and cost-effectiveness, MSAC did not support A1-PI for the treatment of A1-PI deficiency.

The MSAC Public Summary Document setting out the basis for this MSAC advice can be found at

On 14 March 2019, JBC agreed that, on the basis of the advice received from MSAC in relation to the submitted proposals, A1-PI products should not be funded under the National Blood Agreement at this time.

The advice from MSAC and the JBC decision based on that advice do not preclude resubmission of proposals with further evidence, in accordance with ordinary MSAC processes described at